drugset / Trial / NCT07636772
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.
Timeline
- Start
- 2026-06-22
- Primary completion
- 2028-08-24
- Completion
- 2028-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK146D1 | Unknown | — | — |
| Subject | Ivonescimab | Monoclonal antibody | — | — |